|Bid||37.00 x 800|
|Ask||58.80 x 2900|
|Day's Range||42.48 - 44.34|
|52 Week Range||30.00 - 50.05|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.50|
Yahoo Finance's Julie Hyman highlights today's stocks on the move in midday trading.
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would ...
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced positive data from the open-label extension (OLE) of the Phase 2 OASIS trial of its investigational drug candidate etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC). Overall, etrasimod demonstrated durable, long-term clinical remission and was generally safe and well tolerated in this trial. This was a 34-week open-label extension evaluating the long-term safety, tolerability and efficacy of etrasimod in 118 subjects (84% of OASIS study completers) who completed the 12-week Phase 2 OASIS randomized, placebo-controlled trial.
SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:30 AM PST. A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry. "Manmeet brings deep financial and business expertise to the board, and we are thrilled to welcome him," said Tina Nova, Chairman of the Board of Directors of Arena.
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
In 2016 Amit Munshi was appointed CEO of Arena Pharmaceuticals Inc (NASDAQ:ARNA). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
SAN DIEGO, Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the appointments of Robert Lisicki as Executive Vice President and Chief Commercial Officer, and Paul K. Audhya, MD, MBA, as Senior Vice President, Medical Affairs. Mr. Lisicki will report to Amit D. Munshi, Arena's President and Chief Executive Officer, and Dr. Audhya will report to Preston Klassen, MD, M.H.S., Executive Vice President, Research and Development and Chief Medical Officer.
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
SAN DIEGO, Calif. , Nov. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences: ...
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Pharmaceutical companies Arena Pharmaceuticals and Sonoma Pharmaceuticals were in the green on Thursday. While Sonoma did not have any news to note, Arena Pharmaceuticals announced that it has entered into a lucrative licensing agreement with United Therapeutics. Arena Pharmaceuticals, Inc. shares were up 22.62% yesterday on around 4.7 million shares traded.
The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.